United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

akorn - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc.a - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

henry schein, inc. - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

provepharm inc. - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - anticholium® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: - alcohol - tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) - amanita pantherina and amanita muscaria - tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) - antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) - neuroleptic drugs (especially butyrophenones) - benzodiazepines - tolterodine, oxybutynine - amantadine, diphenhydramine - baclofen - 4-hydroxybutyric acid (ghb) - inhalation anesthetics - ketamine - 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: - central anticholinergic syndrome (cas) - delayed postoperative awakening - shivering anticholium® should not be used in the presence of hypersensitivity to physostigmine salicylate, bronchial asthma, ulcers associated with tissue destruction (gang

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - physostigmine salicylate 0.5 mg/ml - solution for injection - 1 mg/2ml - active: physostigmine salicylate 0.5 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - physostigmine salicylate - solution for injection - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - physostigmine salicylate - solution for injection - 2mg/1ml